Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or ...

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today.

We maintain our fair value estimate of JPY 4,700. We estimate revenue will be about JPY 4.8 trillion at the end of fiscal 2034. We expect Takeda to mostly replace its current leading therapies ...

The Irish arm of pharma firm, Takeda last year took a €37.2 million hit to profits after mothballing fresh manufacturing capacity at its Grange Castle site in south county Dublin. New accounts ...

From the commercial standpoint, Takeda and Protagonist project Rusfertide to generate up to $1-2 billion in the U.S. at peak sales (see image below). Given the current partnership agreement, ...

Harmony Biosciences has named Adam Zaeske its next chief commercial officer, luring the Takeda veteran back from Europe to lead a push to turn Wakix into a blockbuster and prepare to launch other ...

Meanwhile, Morrow pointed to the Japanese drugmaker’s successful partnership with Hong Kong-based Hutchmed, in which Takeda paid $400 million upfront for commercial rights outside of China to a ...

Takeda's new building at 585 Kendall has reached a construction milestone. Together with Suffolk Construction, Takeda, and Global Arts Live, BioMed Realty hosted a topping-off ceremony on Jan. 21.

Takeda, founded in 1781 in Osaka, Japan, operates in about 80 countries. The company established a commercial presence in India 13 years ago in Gurugram, currently employing around 200 people.

They chose Takeda because they believe the Japanese pharma giant has the development and commercial infrastructure to maximize the asset’s value by pursuing broader opportunities than Keros ...

Takeda will be responsible for all development, manufacturing and commercialization as of the effective date of the agreement. Takeda will provide Keros Therapeutics with an upfront payment of $200 ...